[go: up one dir, main page]

CL2017002413A1 - Receptor antigénico quimérico - Google Patents

Receptor antigénico quimérico

Info

Publication number
CL2017002413A1
CL2017002413A1 CL2017002413A CL2017002413A CL2017002413A1 CL 2017002413 A1 CL2017002413 A1 CL 2017002413A1 CL 2017002413 A CL2017002413 A CL 2017002413A CL 2017002413 A CL2017002413 A CL 2017002413A CL 2017002413 A1 CL2017002413 A1 CL 2017002413A1
Authority
CL
Chile
Prior art keywords
antigenic receptor
chimeric antigenic
chimeric
receptor
car
Prior art date
Application number
CL2017002413A
Other languages
English (en)
Inventor
Martin Pulé
Shaun Cordoba
Original Assignee
Ucl Business Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucl Business Plc filed Critical Ucl Business Plc
Publication of CL2017002413A1 publication Critical patent/CL2017002413A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4251—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/23—On/off switch
    • A61K2239/24—Dimerizable CARs; CARs with adapter
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

<p>La presente invención se relaciona con un receptor antigénico quimérico (CAR) que comprende un dominio espaciador particular, el cual ocasiona la formación de moléculas de CAR multimérico en la superficie celular</p>
CL2017002413A 2015-03-23 2017-09-25 Receptor antigénico quimérico CL2017002413A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1504840.8A GB201504840D0 (en) 2015-03-23 2015-03-23 Chimeric antigen receptor

Publications (1)

Publication Number Publication Date
CL2017002413A1 true CL2017002413A1 (es) 2018-03-16

Family

ID=53052211

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017002413A CL2017002413A1 (es) 2015-03-23 2017-09-25 Receptor antigénico quimérico

Country Status (21)

Country Link
US (1) US11058722B2 (es)
EP (1) EP3274366B8 (es)
JP (3) JP6675417B2 (es)
KR (1) KR102174280B1 (es)
CN (1) CN107406518B (es)
AU (1) AU2016238583B2 (es)
BR (1) BR112017018252A2 (es)
CA (1) CA2978852C (es)
CL (1) CL2017002413A1 (es)
DK (1) DK3274366T3 (es)
ES (1) ES2773527T3 (es)
GB (1) GB201504840D0 (es)
HU (1) HUE047929T2 (es)
IL (1) IL254254B (es)
MX (1) MX371384B (es)
PL (1) PL3274366T3 (es)
PT (1) PT3274366T (es)
RU (1) RU2752880C2 (es)
SG (1) SG11201706940QA (es)
WO (1) WO2016151315A1 (es)
ZA (1) ZA201705682B (es)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10975162B2 (en) 2014-03-06 2021-04-13 Autolus Limited Chimeric antigen receptor
US11385233B2 (en) 2015-03-05 2022-07-12 Autolus Limited Methods of depleting malignant T-cells
US11885806B2 (en) 2014-03-05 2024-01-30 Autolus Limited Method for depleting malignant T-cells

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201505858VA (en) 2013-01-28 2015-09-29 St Jude Childrens Res Hospital A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
GB201405845D0 (en) 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
WO2015174928A1 (en) 2014-05-15 2015-11-19 National University Of Singapore Modified natural killer cells and uses thereof
GB201415347D0 (en) 2014-08-29 2014-10-15 Ucl Business Plc Signalling system
GB201501936D0 (en) * 2015-02-05 2015-03-25 Ucl Business Plc Signalling system
CN107995913B (zh) 2015-05-18 2022-02-11 T细胞受体治疗公司 使用融合蛋白对tcr重编程的组合物和方法
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
GB201610512D0 (en) 2016-06-16 2016-08-03 Autolus Ltd Chimeric antigen receptor
US11242376B2 (en) 2016-08-02 2022-02-08 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
WO2018067993A1 (en) 2016-10-07 2018-04-12 TCR2 Therapeutics Inc. Compositions and methods for t-cell receptors reprogramming using fusion proteins
JP7291396B2 (ja) 2016-11-22 2023-06-15 ティーシーアール２ セラピューティクス インク． 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
JP7256749B2 (ja) 2017-03-27 2023-04-12 ナショナル ユニヴァーシティー オブ シンガポール ナチュラルキラー細胞免疫療法における切断されたｎｋｇ２ｄキメラ受容体及びその使用
RU2019128544A (ru) 2017-03-27 2021-04-28 Нэшнл Юниверсити Оф Сингапур Линии стимулирующих клеток для ex vivo размножения и активации клеток-натуральных киллеров
CN110678551A (zh) * 2017-03-29 2020-01-10 阳光溪流研究所 经改造的t-细胞调节分子及其使用方法
CA3062506A1 (en) 2017-05-12 2019-05-23 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
EP3662055A1 (en) * 2017-08-02 2020-06-10 Autolus Limited Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed
WO2019086394A1 (en) 2017-11-01 2019-05-09 F. Hoffmann-La Roche Ag The compbody - a multivalent target binder
GB201801831D0 (en) * 2018-02-05 2018-03-21 Autolus Ltd Chimeric receptor
AU2019219454A1 (en) 2018-02-09 2020-08-27 National University Of Singapore Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
SG11202008976YA (en) 2018-04-02 2020-10-29 Nat Univ Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
AU2019266398A1 (en) 2018-05-11 2020-11-19 Crispr Therapeutics Ag Methods and compositions for treating cancer
WO2019220109A1 (en) 2018-05-15 2019-11-21 Autolus Limited Chimeric antigen receptor
GB201807870D0 (en) 2018-05-15 2018-06-27 Autolus Ltd A CD79-specific chimeric antigen receptor
CA3109630A1 (en) 2018-08-16 2020-02-20 Memorial Sloan-Kettering Cancer Center Leucine zipper-based compositions and methods of use
WO2020044239A1 (en) 2018-08-29 2020-03-05 National University Of Singapore A method to specifically stimulate survival and expansion of genetically-modified immune cells
CN109265550B (zh) * 2018-09-25 2020-09-15 华东师范大学 Bcma抗体、嵌合抗原受体和药物
NZ773507A (en) 2018-09-27 2025-09-26 Autolus Ltd Chimeric antigen receptor
WO2020070289A1 (en) * 2018-10-05 2020-04-09 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
KR20210075117A (ko) * 2018-10-05 2021-06-22 세인트 안나 킨더크렙스포르슝 키메라 항원 수용체(car) 그룹
GB201817822D0 (en) 2018-10-31 2018-12-19 Autolus Ltd Binding domain
AU2020224160A1 (en) * 2019-02-21 2021-08-26 John M. LUK Artificial immunosurveillance chimeric antigen receptor (AI-CAR) and cells expressing the same
BR112021017537A2 (pt) 2019-03-05 2021-12-14 Nkarta Inc Receptores de antígeno quimérico dirigidos a cd19 e usos dos mesmos em imunoterapia
AU2020240132A1 (en) 2019-03-21 2021-09-16 Regeneron Pharmaceuticals, Inc. Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergy
SG11202112032WA (en) 2019-04-30 2021-11-29 Crispr Therapeutics Ag Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
GB201919017D0 (en) 2019-12-20 2020-02-05 Autolus Ltd Cell
CN111234033B (zh) * 2020-01-21 2021-05-11 南京北恒生物科技有限公司 多链嵌合抗原受体及其用途
GB202004263D0 (en) 2020-03-24 2020-05-06 Autolus Ltd Antibody conjugate
GB202005216D0 (en) 2020-04-08 2020-05-20 Autolus Ltd Cell
GB202006820D0 (en) 2020-05-07 2020-06-24 Autolus Ltd Cell
GB202017649D0 (en) 2020-11-09 2020-12-23 Autolus Ltd Polypeptide
US12144827B2 (en) 2021-02-25 2024-11-19 Lyell Immunopharma, Inc. ROR1 targeting chimeric antigen receptor
US20250288672A1 (en) * 2021-03-24 2025-09-18 Raymond Liu Humanized synthetic notch receptors with augmented transactivation domains and uses thereof
GB202115329D0 (en) * 2021-10-25 2021-12-08 Autolus Ltd Chimeric cytokine receptor
WO2024019961A1 (en) * 2022-07-18 2024-01-25 Cargo Therapeutics, Inc. Cd2 recruiting chimeric antigen receptors and fusion proteins
WO2025160340A2 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025160324A2 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7081443B2 (en) 2002-05-21 2006-07-25 Korea Advanced Institutes Of Science And Technology (Kaist) Chimeric comp-ang1 molecule
WO2010102518A1 (zh) 2009-03-13 2010-09-16 北京表源生物技术有限公司 一种融合蛋白多聚体
KR101156085B1 (ko) * 2010-01-29 2012-06-20 국립암센터 ４－１ｂｂ리간드（４－１ｂｂｌ）오중합체 및 이의 용도
US10745467B2 (en) * 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
WO2013051718A1 (ja) * 2011-10-07 2013-04-11 国立大学法人三重大学 キメラ抗原受容体
MA37681B2 (fr) * 2012-05-25 2020-07-29 Cellectis Procédés pour modifier des lymphocytes t résistants allogéniques et immunosuppresseurs pour l'immunothérapie
DK2893004T3 (en) * 2012-09-04 2019-02-04 Cellectis MULTI-CHAIN CHEMICAL ANTIGEN RECEPTOR AND APPLICATIONS THEREOF
KR102132246B1 (ko) * 2013-02-15 2020-07-09 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 키메라 항원 수용체 및 이의 이용 방법
CN103145849B (zh) 2013-02-18 2014-06-11 冯振卿 嵌合抗原受体及其用途
HRP20201906T1 (hr) * 2013-12-20 2021-04-02 Fred Hutchinson Cancer Research Center Označene kimerne efektorske molekule i njihovi receptori
WO2015105522A1 (en) 2014-01-13 2015-07-16 Forman Stephen J Chimeric antigen receptors (cars) having mutations in the fc spacer region and methods for their use
GB201415347D0 (en) 2014-08-29 2014-10-15 Ucl Business Plc Signalling system
GB201610512D0 (en) 2016-06-16 2016-08-03 Autolus Ltd Chimeric antigen receptor

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11885806B2 (en) 2014-03-05 2024-01-30 Autolus Limited Method for depleting malignant T-cells
US11885807B2 (en) 2014-03-05 2024-01-30 Autolus Limited Method for depleting malignant T-cells
US11982672B2 (en) 2014-03-05 2024-05-14 Autolus Limited Methods
US11982673B2 (en) 2014-03-05 2024-05-14 Autolus Limited Methods
US10975162B2 (en) 2014-03-06 2021-04-13 Autolus Limited Chimeric antigen receptor
US11879016B2 (en) 2014-03-06 2024-01-23 Autolus Limited Chimeric antigen receptor
US11385233B2 (en) 2015-03-05 2022-07-12 Autolus Limited Methods of depleting malignant T-cells

Also Published As

Publication number Publication date
EP3274366B8 (en) 2020-02-12
SG11201706940QA (en) 2017-09-28
DK3274366T3 (da) 2020-02-10
PT3274366T (pt) 2020-01-30
JP2018510639A (ja) 2018-04-19
MX2017010552A (es) 2018-03-14
CA2978852C (en) 2021-10-19
IL254254B (en) 2021-04-29
CN107406518B (zh) 2022-02-01
WO2016151315A1 (en) 2016-09-29
EP3274366B1 (en) 2019-12-11
MX371384B (es) 2020-01-28
US20180050065A1 (en) 2018-02-22
JP6675417B2 (ja) 2020-04-01
CN107406518A (zh) 2017-11-28
GB201504840D0 (en) 2015-05-06
US11058722B2 (en) 2021-07-13
IL254254A0 (en) 2017-10-31
HUE047929T2 (hu) 2020-05-28
EP3274366A1 (en) 2018-01-31
JP2023021396A (ja) 2023-02-10
NZ735267A (en) 2021-04-30
PL3274366T3 (pl) 2020-06-15
BR112017018252A2 (pt) 2018-04-10
RU2752880C2 (ru) 2021-08-11
AU2016238583B2 (en) 2020-08-13
AU2016238583A1 (en) 2017-09-28
KR20180009738A (ko) 2018-01-29
CA2978852A1 (en) 2016-09-29
JP2020048588A (ja) 2020-04-02
RU2017132978A (ru) 2019-04-08
ES2773527T3 (es) 2020-07-13
RU2017132978A3 (es) 2019-06-24
ZA201705682B (en) 2018-12-19
KR102174280B1 (ko) 2020-11-04

Similar Documents

Publication Publication Date Title
CL2017002413A1 (es) Receptor antigénico quimérico
CY1125032T1 (el) Υποκινητης mnd χιμαιρικους υποδοχεις αντιγονου
CY1122398T1 (el) Συνδυαστικες θεραπειες με αντισωματα anti-cd38
CL2017001393S1 (es) Automovil
CL2017001185S1 (es) Automovil
BR112018006471A2 (pt) compostos úteis como moduladores de trpm8
MX2017006233A (es) Celula.
PT3161007T (pt) Constructos de anticorpos multi-específicos.
CL2017002099S1 (es) Automóvil.
EA201891209A1 (ru) Модуляторы хемокиновых рецепторов
PL3126380T3 (pl) Układ sygnalizacji chimerycznego receptora antygenowego (CAR)
MX378859B (es) Receptores de antigenos quimericos.
CL2016000221A1 (es) Anticuerpos anti-fgfr2iiib afucosilados.
EP2970412A4 (en) ACTIVATION OF BIOLUMINESCENCE BY STRUCTURAL COMPLEMENTATION
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
DK3551926T3 (da) Hydrogenoptankningssystem
BR112017012364A2 (pt) pré-tratamento rápido.
DK3551925T3 (da) Hydrogenoptankningssystem
EA201700142A1 (ru) Полимерная композиция для слоя элемента слоя
EA201690245A1 (ru) Оптимизированный способ получения композиции, содержащей изомальтулозу
MX383890B (es) Partículas de resinato de fenilefrina.
MX2017013454A (es) Deteccion de moleculas de acido nucleico.
EA201692246A1 (ru) Способ получения 2,6-диметилбензохинона
MX385652B (es) Composicion heterofasica.
CL2016000940A1 (es) Predicción de rasgos híbridos.